These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 20447069

  • 1. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies.
    Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG, Fugazzola L.
    Clin Endocrinol (Oxf); 2010 May; 72(5):702-8. PubMed ID: 20447069
    [Abstract] [Full Text] [Related]

  • 2. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
    Mechler C, Bounacer A, Suarez H, Saint Frison M, Magois C, Aillet G, Gaulier A.
    Br J Cancer; 2001 Dec 14; 85(12):1831-7. PubMed ID: 11747322
    [Abstract] [Full Text] [Related]

  • 3. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
    Durand S, Ferraro-Peyret C, Joufre M, Chave A, Borson-Chazot F, Selmi-Ruby S, Rousset B.
    Endocr Relat Cancer; 2009 Jun 14; 16(2):467-81. PubMed ID: 19208736
    [Abstract] [Full Text] [Related]

  • 4. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E.
    Clin Endocrinol (Oxf); 2006 Jan 14; 64(1):105-9. PubMed ID: 16402937
    [Abstract] [Full Text] [Related]

  • 5. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.
    Clin Endocrinol (Oxf); 2008 Apr 14; 68(4):618-34. PubMed ID: 18070147
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
    Rumiantsev PO, Zaletaev DV, Vasil'ev EV, Saenko VA, Il'in AA, Rumiantseva UV, Abrosimov AIu, Medvedev VS.
    Vopr Onkol; 2006 Apr 14; 52(2):145-9. PubMed ID: 17195637
    [Abstract] [Full Text] [Related]

  • 8. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T, Jin M, Fahey TJ, Zarnegar R.
    Ann Surg Oncol; 2012 Mar 14; 19(3):973-80. PubMed ID: 21879273
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT.
    Clin Endocrinol (Oxf); 2005 Oct 14; 63(4):461-6. PubMed ID: 16181240
    [Abstract] [Full Text] [Related]

  • 11. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
    Sheils OM, O'Leary JJ, Sweeney EC.
    J Pathol; 2000 Sep 14; 192(1):32-6. PubMed ID: 10951397
    [Abstract] [Full Text] [Related]

  • 12. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
    Liu RT, Chou FF, Wang CH, Lin CL, Chao FP, Chung JC, Huang CC, Wang PW, Cheng JT.
    Thyroid; 2005 Apr 14; 15(4):326-35. PubMed ID: 15876154
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R.
    Endocr Relat Cancer; 2006 Jun 14; 13(2):455-64. PubMed ID: 16728573
    [Abstract] [Full Text] [Related]

  • 16. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
    Sheu SY, Vogel E, Worm K, Grabellus F, Schwertheim S, Schmid KW.
    Histopathology; 2010 Apr 14; 56(5):632-40. PubMed ID: 20459574
    [Abstract] [Full Text] [Related]

  • 17. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F.
    J Clin Endocrinol Metab; 2004 May 14; 89(5):2414-20. PubMed ID: 15126572
    [Abstract] [Full Text] [Related]

  • 18. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU, Oler G, Nozima BH, Moysés RA, Cerutti JM.
    Eur J Endocrinol; 2015 Oct 14; 173(4):525-40. PubMed ID: 26338373
    [Abstract] [Full Text] [Related]

  • 19. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 20. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
    Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R.
    Endocr Relat Cancer; 2008 Mar 01; 15(1):191-205. PubMed ID: 18310287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.